People given either 2.4 mg or 3 mg of liraglutide per day maintained a weight loss of 17.6 lbs after two (2) years according to a recent study from Denmark. Liraglutide (brand name Victoza) is a human GLP-1 analog that is a once-daily injectable medication. Read the entire article | Email this article

People given 3 mg of liraglutide per day lost 12.8 lbs more after one (1) year than those given a placebo according to a recent study from Denmark. Liraglutide (brand name Victoza) is a human GLP-1 analog that is a once-daily injectable medication. Read the entire article | Email this article

People given 3 mg of liraglutide per day lost 8.4 lbs more after one (1) year than those given the fat-blocking drug, orlistat, according to a recent study from Denmark. Liraglutide (brand name Victoza) is a human GLP-1 analog that is a once-daily injectable medication. Read the entire article | Email this article

People given 3 mg of liraglutide per day lost 7.3 lbs more after two (2) years than those given the fat-blocking drug, orlistat, according to a recent study from Denmark. Liraglutide (brand name Victoza) is a human GLP-1 analog that is a once-daily injectable medication. Read the entire article | Email this article

At a dose of 1.2 mg per day, the once-daily diabetes drug called liraglutide caused diabetics to lose an average of 7.1 pounds in a year if they experienced nausea for more than seven days, and an average of 4.1 pounds if they did not.

The drug is not yet approved for sale in the U.S.

At a dose of 1.8 mg, the average weight loss was 7.5 pounds for those who experienced nausea for more than seven days, and an average of 5 pounds for those who did not.

This compared to a weight loss of 3.1 pounds for those given Amaryl (glimepiride) who experienced nausea for more than 7 days, and a weight gain of 2.7 pounds for those who did not. Read the entire article | Email this article

The experimental drug liraglutide, a once-a-day human GLP-1 analogue for the treatment of type 2 diabetes, combined with diet caused a weight loss of roughly 17 pounds after one year compared to a weight loss of roughly 4-5 pounds for those given a placebo according to a report from Reuters.

Weight loss after the first five months of the study had been roughly 16 pounds versus 9 pounds for those given a placebo according to Reuters.

However, the drug company's website shows the results of a (different?) study of the drug in Type 2 diabetics which shows a weight loss of only 5.4 pounds for those given 1.8 mg per day of liraglutide versus 4.5 pounds for those given 1.2 mg of liraglutide versus a weight gain of 2.5 pounds for those given another diabetes drug called glimepiride.

On May 23, 2008, Novo Nordisk submitted an applicationto the US Food and Drug Administration for approval of the drug. Read the entire article | Email this article